SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000905718-10-000133
Filing Date
2010-06-28
Accepted
2010-06-28 15:30:15
Documents
1

Document Format Files

Seq Description Document Type Size
1 FURIEX061610 furiex.htm SC 13D 129158
  Complete submission text file 0000905718-10-000133.txt   131181
Mailing Address 599 LEXINGTON AVENUE SUITE 4100 NEW YORK NY 10022
Business Address 599 LEXINGTON AVENUE SUITE 4100 NEW YORK NY 10022 2124462460
TYNDALL CAPITAL PARTNERS L P (Filed by) CIK: 0001219314 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 3900 PARAMOUNT PARKWAY SUITE 150 MORRISVILLE NC 27560
Business Address 3900 PARAMOUNT PARKWAY SUITE 150 MORRISVILLE NC 27560 919-456-7800
Furiex Pharmaceuticals, Inc. (Subject) CIK: 0001484478 (see all company filings)

IRS No.: 271197863 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-85529 | Film No.: 10919947
SIC: 2834 Pharmaceutical Preparations